Virchows Archiv

, 455:469

Borderline and malignant phyllodes tumors display similar promoter methylation profiles

  • Jo-Heon Kim
  • Yoo Duk Choi
  • Ji Shin Lee
  • Jae Hyuk Lee
  • Jong Hee Nam
  • Chan Choi
  • Min Ho Park
  • Jung Han Yoon
Original Article

Abstract

Mammary phyllodes tumors (PTs) are uncommon fibroepithelial neoplasms. On the basis of histologic criteria, PTs can be divided into benign, borderline, and malignant groups; however, the histologic distinction of PTs is often difficult and arbitrary. In breast cancer, promoter hypermethylation is a common phenomenon, but there are no data available concerning methylation status in PTs. The aim of this study was to assess whether the methylation profiles support the classification of PTs into three subgroups. A multiplex, nested, methylation-specific polymerase chain reaction approach was used to examine promoter methylation of five genes (GSTP1, HIN-1, RAR-β, RASSF1A, and Twist) in 87 PTs (54 benign, 23 borderline, and 10 malignant). Immunohistochemical staining for GSTP1 was performed using tissue microarray blocks to determine whether GSTP1 promoter hypermethylation correlated with loss of GSTP1 expression. There was a trend of increasing methylation frequency with increasing grade of PTs. The methylation frequency of all genes and the mean number of methylated genes in borderline and malignant PTs were higher than those in benign PTs; however, there were no statistically significant differences between borderline and malignant PTs. GSTP1 promoter hypermethylation was associated with loss of GSTP1 expression (p < 0.001). These results suggest that PTs segregate into only two groups on the basis of their methylation profiles: the benign group and the combined borderline/malignant group.

Keywords

Breast tumor Phyllodes Classification Methylation 

References

  1. 1.
    Bellocq JP, Magro G (2003) Fibroepithelial tumors. In: Tavassoli FA, Devilee P (eds) World health organization classification of tumors: tumors of the breast and female genital organs. IARC, Lyon, pp 99–103Google Scholar
  2. 2.
    Layfield LJ, Hart J, Neuwirth H, Bohman R, Trumbull WE, Giuliano AE (1989) Relation between DNA ploidy and the clinical behavior of phyllodes tumors. Cancer 64:1486–1489CrossRefPubMedGoogle Scholar
  3. 3.
    Parker SJ, Harries SA (2001) Phyllodes tumours. Postgrad Med J 77:428–435CrossRefPubMedGoogle Scholar
  4. 4.
    Rosen PP (2001) Fibroepithelial neoplasms. In: Rosen PP (ed) Rosen’s breast pathology, 2nd edn. Lippincott, Williams & Wilkins, Philadelphia, pp 163–200Google Scholar
  5. 5.
    Kleer CG, Giordano TJ, Braun T, Oberman HA (2001) Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Mod Pathol 14:185–190CrossRefPubMedGoogle Scholar
  6. 6.
    Sawyer EJ, Poulsom R, Hunt FT et al (2003) Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol 200:59–64CrossRefPubMedGoogle Scholar
  7. 7.
    Tse GM, Lui PC, Lee CS et al (2004) Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum Pathol 35:1053–1057CrossRefPubMedGoogle Scholar
  8. 8.
    Tan PH, Jayabaskar T, Yip G et al (2005) p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 18:1527–1534CrossRefPubMedGoogle Scholar
  9. 9.
    Tse GM, Tsang AK, Putti TC et al (2005) Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 58:185–189CrossRefPubMedGoogle Scholar
  10. 10.
    Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ (2006) Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med 130:1516–1521PubMedGoogle Scholar
  11. 11.
    Kersting C, Kuijper A, Schmidt H et al (2006) Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 86:54–61CrossRefPubMedGoogle Scholar
  12. 12.
    Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462–5482CrossRefPubMedGoogle Scholar
  13. 13.
    Laé M, Vincent-Salomon A, Savignoni A et al (2007) Phyllodes tumors of the breast segregate in two groups according to genetic criteria. Mod Pathol 20:435–444CrossRefPubMedGoogle Scholar
  14. 14.
    Jones AM, Mitter R, Springall R, Graham T et al (2008) A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 214:533–544CrossRefPubMedGoogle Scholar
  15. 15.
    Lv S, Niu Y, Wei L, Liu Q, Wang X, Chen Y (2008) Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study. Breast Cancer Res Treat 112:411–418CrossRefPubMedGoogle Scholar
  16. 16.
    Wajed SA, Laird PW, DeMeester TR (2001) DNA methylation: an alternative pathway to cancer. Ann Surg 234:10–20CrossRefPubMedGoogle Scholar
  17. 17.
    Momparler RL, Bovenzi V (2000) DNA methylation and cancer. J Cell Physiol 183:145–154CrossRefPubMedGoogle Scholar
  18. 18.
    Lee JS, Lo PK, Fackler MJ et al (2007) A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women. Cancer Biol Ther 6:1114–11120CrossRefPubMedGoogle Scholar
  19. 19.
    Lee JS, Fackler MJ, Teo WW et al (2008) Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis. Cancer Biol Ther 7:1398–1406CrossRefPubMedGoogle Scholar
  20. 20.
    Fackler MJ, Malone K, Zhang Z et al (2006) Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12:3306–3310CrossRefPubMedGoogle Scholar
  21. 21.
    House MG, Herman JG, Guo MZ et al (2003) Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 238:423–431PubMedGoogle Scholar
  22. 22.
    Fackler MJ, McVeigh M, Evron E et al (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107:970–975CrossRefPubMedGoogle Scholar
  23. 23.
    Lee JS (2007) GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch 450:637–642CrossRefPubMedGoogle Scholar
  24. 24.
    Huang J, Tan PH, Thiyagarajan J, Bay BH (2003) Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 16:558–565CrossRefPubMedGoogle Scholar
  25. 25.
    Palmisano WA, Divine KK, Saccomanno G et al (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954–5958PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Jo-Heon Kim
    • 1
  • Yoo Duk Choi
    • 1
  • Ji Shin Lee
    • 1
    • 3
  • Jae Hyuk Lee
    • 1
  • Jong Hee Nam
    • 1
  • Chan Choi
    • 1
  • Min Ho Park
    • 2
  • Jung Han Yoon
    • 2
  1. 1.Department of PathologyChonnam National University Medical School and Research Institute of Medical SciencesGwangjuSouth Korea
  2. 2.Department of SurgeryChonnam National University Medical School and Research Institute of Medical SciencesGwangjuSouth Korea
  3. 3.Department of PathologyChonnam National University Hwasun HospitalHwasun-gunRepublic of Korea

Personalised recommendations